Identifying patients at risk for esophageal cancer through biomarker analysis
Official title: Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus
Funded at University of California, San Francisco · NIH-10988229 · Data updated 2026-11-12
This study is looking for signs in tissue samples from people with Barrett's esophagus to help figure out who might be more likely to develop cancer, so that those at higher risk can get better screening and treatment.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 28, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $553,189 |
| NIH project number | 5R37CA269649-03 |
| Project ID | NIH-10988229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Barrett's esophagus, particularly those with non-dysplastic Barrett's esophagus or low-grade dysplasia.
✕Less likely to help
Patients without Barrett's esophagus or those with advanced esophageal cancer may not benefit from this research.
What this research studies
This research focuses on Barrett's esophagus, a condition that can lead to esophageal adenocarcinoma, which is a serious type of cancer. The study aims to identify specific biomarkers that can help determine which patients with Barrett's esophagus are at higher risk of developing cancer. By analyzing tissue samples from patients, researchers will develop and validate a biomarker panel that can effectively stratify risk. This approach could lead to better screening and treatment options for those at risk.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more personalized treatment for patients at risk of esophageal cancer.
How similar studies have gone: Previous research has shown promise in using biomarkers for cancer risk stratification, indicating that this approach may be effective.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Stachler, Matthew D — University of California, San Francisco
- Study coordinator: Stachler, Matthew D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.